HAO BAI INTL (08431): Yuan Wei emphasizes appointment as chairman of the nomination committee
Haw Par Corporation (08431) announced that effective from December 5, 2025, the following changes have been made to the Nomination Committee:
- Ms. Wang Yonghong, an executive director of the company, has been appointed as a member of the Nomination Committee;
- Mr. Wu Yunle, an executive director and Chairman of the Nomination Committee, has stepped down as Chairman of the Nomination Committee;
- Mr. Yuan Weiqiang, an independent non-executive director and member of the Nomination Committee, has been reassigned as the Chairman of the Nomination Committee.
HAO BAI INTL(08431) announces that, effective from December 5, 2025, the Nomination Committee of the company has undergone the following changes:
- Ms. Wang Yonghong, an executive director of the company, has been appointed as a member of the Nomination Committee.
- Mr. Wu Yunle, an executive director of the company and the former chairman of the Nomination Committee, is no longer serving as the chairman of the Nomination Committee.
- Mr. Yuan Weiqiang, an independent non-executive director of the company and a member of the Nomination Committee, has been reassigned as the chairman of the Nomination Committee.
Related Articles
HAOHAI BIOTEC (06826) spent 837,000 Hong Kong dollars to repurchase 30,500 shares on December 5th.
The controlling shareholder of KONTA CHINA (01312) remains unchanged. Shanxi Construction Investment holds 52.44% of the shares and Shanxi Communications holds 90% of the shares have been transferred to the Shanxi Provincial State-owned Assets Supervision and Administration Commission.
CSPC PHARMA (01093): GLP-1/GIP receptor biased agonist dual peptide injection approved for clinical trials in the United States.
HAOHAI BIOTEC (06826) spent 837,000 Hong Kong dollars to repurchase 30,500 shares on December 5th.
The controlling shareholder of KONTA CHINA (01312) remains unchanged. Shanxi Construction Investment holds 52.44% of the shares and Shanxi Communications holds 90% of the shares have been transferred to the Shanxi Provincial State-owned Assets Supervision and Administration Commission.
CSPC PHARMA (01093): GLP-1/GIP receptor biased agonist dual peptide injection approved for clinical trials in the United States.
